The DUPIXENT® FastStart Program
Accelerating access to DUPIXENT® (dupilumab injection)
for your patients aged 6 months and older
Is your patient eligible for the FastStart Program?
Select an indication to view coverage details:
DUPIXENT® (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1
- DUPIXENT® can be used with or without topical corticosteroids
DUPIXENT® (dupilumab injection) is indicated for the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1
- DUPIXENT® can be used with or without topical corticosteroids
Coverage details for patients with AD2
Please select a province or region:
| Age | Coverage type | |
|---|---|---|
| Public | Private | |
| 12 years + | Post TCS and TCI (EASI 16+ or Special Areas Involvement) | Post TCS and TCI (EASI 16+ or Special Areas Involvement) |
| 6 months – 11 years * Syringe only for >6 months to <2 years. | Post TCS and TCI (EASI 16+ or Special Areas Involvement) | Post TCS and TCI (EASI 16+ or Special Areas Involvement) |
Special Areas (SA) include involvement of face or hands or feet or genitals.
| Age | Coverage type | |
|---|---|---|
| Public | Private | |
| 12 years + | Post Topical (TCS or TCI) AND Post Failure of ONE Immunosuppressant (IS) (Methotrexate OR Cyclosporine OR Azathioprine OR MMF) OR Intolerance to TWO Agents | Post Topical (TCS and TCI):
|
| 6 months – 11 years * Syringe only for >6 months to <2 years. | Post TCS and TCI (any Payer) | |
All private plans and public plans require EASI 16; public also require IGA 3+.
| Age | Coverage type | |
|---|---|---|
| Public | Private | |
| 12 years + | Post Topical (TCS or TCI) (EASI ≥ 7.1) AND Post Failure of ONE Immunosuppressant (IS) (Methotrexate OR Cyclosporine OR Azathioprine OR MMF) OR Intolerance to TWO Agents | Post Topical (TCS and TCI):
|
| 6 months – 11 years * Syringe only for >6 months to <2 years. | Post TCS and TCI (any Payer) | |
All private plans require EASI 16; public plans (12+ age) require EASI 7.1.
| Age | Coverage type | |
|---|---|---|
| Public | Private | |
| 12 years + | Post Topical (TCS or TCI) AND Post Failure of ONE Immunosuppressant (IS) (Methotrexate OR Cyclosporine OR Azathioprine OR MMF) OR Intolerance to TWO Agents | Post Topical (TCS and TCI):
|
| 6 months – 11 years * Syringe only for >6 months to <2 years. | Post TCS and TCI (any Payer) | |
All private and public plans require EASI 16.
| Age | Coverage type | |
|---|---|---|
| Public | Private | |
| 12 years + | Post Topical (2 TCS and 1 TCI) AND Post Failure of ONE Immunosuppressant (IS) (Methotrexate OR Cyclosporine OR Azathioprine OR MMF) OR Intolerance to TWO Agents | Post Topical (TCS and TCI):
|
| 6 months – 11 years * Syringe only for >6 months to <2 years. | Post 2 TCS and 1 TCI (any Payer) | |
All private plans and public plans require EASI 16; public also require IGA 3+.
| Age | Coverage type |
|---|---|
| Private | |
| 12 years + | Post Topical (TCS and TCI):
|
| 6 months – 11 years * Syringe only for >6 months to <2 years. |
All private plans require EASI 16.
Coverage details for patients with PN
Please select a private payer:
| Private |
|---|
Sun Life / Canada Life / Manulife only
|
| Private |
|---|
GreenShield including all plans managed through GreenShield
|
Plans managed through GreenShield include:
- Alberta Retired Teachers’ Association (ARTA)
- Benecaid Health Benefit Solutions Inc.
- Beneva
- Commission de la construction du Québec (CCQ)
- Fraternité des Policiers et Policières de Montréal (FPPM)
- Humania Assurance Inc.
- Industrial Alliance
- McAteer Group of Companies
- RBC Insurance
- Retired Teachers Insurance Plan (RTIP)
- RWAM Insurance Administrators
- Securian Canada
- Wawanesa Insurance
| Private |
|---|
ClaimSecure
|
Clinical use:
Efficacy and safety of DUPIXENT® in pediatric patients with atopic dermatitis below the age of 6 months have not been established.
Contraindications:
Hypersensitivity to DUPIXENT® or to any ingredient in the formulation or component of the container.
Warnings and precautions:
- Reduction of corticosteroid dosage
- Systemic hypersensitivity reactions
- Eosinophilic conditions
- Not studied with live vaccines
- Conjunctivitis and keratitis
- Patients with helminth infection
- Patients with concomitant atopic conditions
- Arthralgia
- Acute asthma symptoms or deteriorating disease
- Pregnant and nursing women
For more information:
Consult the Product Monograph here for important information relating to adverse drug reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-265-7927.
TCS=topical corticosteroids; TCI=topical calcineurin inhibitors; EASI=eczema Area and Severity Index; MMF=mycophenolate mofetil; NIHB=Non-Insured Health Benefits; IGA=Investigator’s Global Assessment; WI-NRS=Worst Itch Numeric Rating Scale; IGA PN-S=Investigator's Global Assessment for Prurigo Nodularis Stage.
References: 1. DUPIXENT® Product Monograph, sanofi-aventis Canada Inc., September 6, 2024. 2. Data on file, sanofi-aventis Canada Inc., August 1, 2024.